

Neu Tec Pharma plc

13 November 2003

Mycograb(R) Clinical Trial: EMEA Update

13 November 2003 - Manchester, UK: NeuTec Pharma plc (NTP.L), the biopharmaceutical company targeting drug-resistant, life-threatening infections, today announces that following recent discussions with the Scientific Advice Working Group ('SAWG') of the European Medicines Evaluation Agency ('EMEA'), regarding the on-going Mycograb(R) clinical trial protocol, that the final guidelines have now been set for the latter part of the trial.

The EMEA has confirmed the following:

- 1) The total number of patients required for the trial will be 160;
- 2) The structure of the trial, incorporating a three month follow-up, is appropriate to demonstrate the safety and clinical efficacy of Mycograb(R); and
- 3) The trial may be used to support an application for market authorization for the following clinical situation - 'Mycograb(R) in combination with amphotericin B for the treatment of invasive candidiasis in immunocompetent intensive care patients.'

Mycograb(R), which has Orphan Drug Status, is currently undergoing international phase II clinical trials for the treatment of life-threatening fungal infections (systemic candidiasis), and has an established safety and efficacy profile. Mycograb(R) is based on a naturally-occurring human antibody response against Hsp90, which helps the body defend itself against life threatening fungal infections. It has reached an advanced stage in the phase II clinical trial designed to assess its use in the treatment of serious fungal infections, currently being conducted in 38 hospitals in Europe and the US.

Prof. James Burnie, Chief Executive Officer of NeuTec, said, 'We are encouraged by the EMEA's interest in the progress of the Mycograb(R) trial and are pleased with the outcome of our recent discussions. Based on the current rate of patient recruitment into the trial, the Board of NeuTec Pharma anticipates that it should be in a position to submit to the EMEA a Mycograb(R) dossier for marketing approval in 2004.'

ENDS

For further details please contact:

NeuTec Pharma plc

www.neutecpharma.com

Professor James Burnie, CEO
Andrew King, Finance Director

0161 276 8827 / 07979 242 819
07771 867890

Financial Dynamics

Ben Atwell / Lucy Briggs

020 7831 3113

Notes to editors:

NeuTec Pharma plc is a biopharmaceutical company formed in 1997 which specialises in the development of genetically recombinant antibodies, or 'grabs', for the treatment of life-threatening infections. In February 2002 the Company's equity was admitted on the Alternative Investment Market ('AIM') of the London Stock Exchange.

The development of NeuTec's products differs from the traditional approach used by conventional pharmaceutical companies that screen numerous chemical compounds for activity against bacteria and fungi. Many of these compounds will be too toxic for human use. In contrast, NeuTec identifies naturally occurring potentially protective antibodies from patients who have recovered from bacterial and fungal infections and then uses these to generate 'grabs' to treat these infections. As a result, these 'grabs' are likely to be intrinsically safer than antibiotics.

NeuTec's two leading drug candidates are Mycograb(R), which targets systemic candidiasis, and Aurograb(R), which targets Staphylococcus aureus including methicillin-resistant Staphylococcus aureus ('MRSA').

NeuTec uses its platform technology Fabtec(R) for the identification of new therapeutic antibody fragments. This technology is available for licensing.